Research programme: ADAPTIR multi-specific therapeutics - Aptevo Therapeutics

Drug Profile

Research programme: ADAPTIR multi-specific therapeutics - Aptevo Therapeutics

Alternative Names: Anti-CD123 x Anti-CD3; Anti-CD19 X Anti-CD-3; Anti-CD86 X mono-IL-10; Anti-HER2 X Anti-CD3; Anti-RON X Anti-CD3; APVO-425; APVO-436; APVO-437; CD79BxDR; CD79BxDR Scorpion™ molecule; CTLA-4 X mono-IL-10; ES-210; ES-425; T-Scorp; TNFR x A2; TNFR x TWEAKR; X1 Anti-TNF-based SCORPION™; X1 TNF-based SCORPION™; X2 CTLA4-based SCORPION™

Latest Information Update: 10 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Trubion Pharmaceuticals
  • Developer Emergent BioSolutions
  • Class Bispecific antibodies; Proteins; Small molecules
  • Mechanism of Action CD19 antigen inhibitors; CD3 antigen inhibitors; CD79 antigen inhibitors; CD86 antigen inhibitors; Cytotoxic T-lymphocyte antigen 4 inhibitors; ERBB 2 receptor antagonists; Glutamate carboxypeptidase II inhibitors; HLA-DR antigen inhibitors; Immunosuppressants; Interleukin 10 inhibitors; Receptor tyrosine kinase-like orphan receptor antagonists; RON protein inhibitors; TNFSF12 protein inhibitors; Tumour necrosis factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 03 Apr 2017 Pharmacokinetics and pharmacodynamics data from preclinical studies in Cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
  • 31 Mar 2017 Research programme is available for licensing as of 31 Mar 2017. http://www.emergentbiosolutions.com
  • 12 Jan 2017 Preclinical development is ongoing in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top